BriaCell Therapeutics (BCT) Stock Price, News & Analysis

Company Overview

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Key Stats

• Today's Range: C$10.60 to C$11.07
• 50-Day Range: C$10.60 to C$10.60
• 52-Week Range: C$3.50 to C$15.75
• Volume: 3,402 shs
• Average Volume: 12,671 shs
• Market Capitalization: C$168.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:BCT
• CIK: N/A
• Web: www.briacell.com
• Phone: +1-604-9211810
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 129.63
• Quick Ratio: 128.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$3.34 per share
• Price / Cash Flow: 3.17
• Book Value: C$3.60 per share
• Price / Book: 2.94

Miscellaneous

• Outstanding Shares: 15,913,000
• Free Float: N/A
• Market Cap: C$168.68 million
• Optionable: Not Optionable
• Beta: N/A